Heron Therapeutics Stock News

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare wit

Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

Heron Therapeutics has made progress in shoring up its balance sheet and cutting expenses, improving its financial position. Revenue growth remains a challenge. The expanded label for Zynrelef and the

Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.

Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech

HRTX's Zynrelef sales are back on track, with potential for significant growth pending approval of a supplemental New Drug Application. Aponvie sales have been underwhelming thus far and probably won'

Heron Therapeutics develops solutions for pain and discomfort associated with chemotherapy and surgery, with four FDA-approved products. The company underwent a leadership change and implemented a pla

Undeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. And this interest goes well beyond the meme-stock phenomenon that characterized much of the market ac

Penny stocks are highly speculative equities priced under $5 per share. They grab attention for their rapid rally potential even if the risks give most investors pause.

The world of penny stocks is interesting, offering the promise of significant returns for those willing to dive into this niche market. There aren't any guarantees that you'll immediately hit it big a

When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Jeff Cohen - Executive Director, Assistant General Counsel and Assistant Secr